Wednesday, April 21, 2021
News
NEWS HOME
»
PRN INDIA
RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.
  SocialTwist Tell-a-Friend  
   

Following review of data from the U.S. Phase 2 study by the FDA, RedHill plans to expand the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 to the U.S.

The study has enrolled over 50% of the targeted 464 patients globally; U.S. study activities expected to expand the study to a total of 8 countries and approximately 40 recruiting sites; Top-line results expected in the second quarter

Opaganib demonstrated dual anti-inflammatory and antiviral activity and targets a human cell component involved in viral replication and is  therefore expected to be effective against emerging viral variants with mutations in the spike protein

TEL AVIV, Israel and RALEIGH, NC, Feb. 23, 2021 /PRNewswire/ --  RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its plans to expand the Company's global Phase 2/3 study of opaganib[1] in patients with severe COVID-19 to the U.S., following U.S. Food and Drug Administration (FDA) review of the data from the U.S. Phase 2 study of opaganib and receipt of its recommendations.    

RedHill Biopharma Logo

Expansion of the global Phase 2/3 study to the U.S. will entail adjustments to the protocol based on the FDA's recommendations and ongoing discussions. The expansion of the study to the U.S. will help further speed-up enrollment, expanding the study to a total of 8 countries and approximately 40 recruiting sites, with additional sites and countries being added. The 464-patient study is over 50% enrolled and is expected to deliver top-line data in the second quarter of 2021.

The global Phase 2/3 study recently underwent a positive DSMB futility review, which is suggestive that the study has the potential for a positive outcome. RedHill recently announced positive top-line safety and efficacy data from the non-powered U.S. Phase 2 study with opaganib in patients with COVID-19 pneumonia, in which opaganib demonstrated greater improvement in reducing oxygen requirement by end of treatment on Day 14 across key primary and secondary efficacy outcomes. The Phase 2 data also showed no material safety differences between the opaganib and placebo treatment arms - further adding to the growing safety database for opaganib.

Opaganib is a novel, orally-administered sphingosine kinase-2 (SK2) inhibitor with demonstrated antiviral, anti-inflammatory, and anti-thrombotic activity, that targets a human cell component involved in viral replication and is therefore expected to be effective against emerging viral variants with mutations in the spike protein.

About Opaganib (Yeliva ®, ABC294640)

Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with demonstrated dual anti-inflammatory and antiviral activity that targets a host cell component of viral replication, potentially minimizing the likelihood of viral resistance. Opaganib has also shown anticancer activity and has the potential to target multiple oncology, viral, inflammatory, and gastrointestinal indications.

Opaganib  received Orphan Drug designation from the U.S. FDA for the treatment of cholangiocarcinoma and is being evaluated in a Phase 2a study in advanced cholangiocarcinoma and in a Phase 2 study in prostate cancer. Opaganib is also being evaluated as a treatment for COVID-19 pneumonia in a global Phase 2/3 study and has demonstrated positive safety and efficacy signals in preliminary top-line data from a U.S. Phase 2 study.

Preclinical data have demonstrated anti-inflammatory, antiviral and anti-thrombotic activities of opaganib, with the potential to ameliorate inflammatory lung disorders, such as pneumonia, and mitigate pulmonary fibrotic damage. Opaganib demonstrated potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19,  completely inhibiting viral replication in an in vitro model of human lung bronchial tissue. Opaganib also demonstrated reduced blood clot length, weight and total thrombus score in a preclinical model of Acquired Respiratory Distress Syndrome. Additionally, preclinical in vivo studies[2] have demonstrated that opaganib decreased fatality rates from influenza virus infection and ameliorated Pseudomonas aeruginosa-induced lung injury by reducing the levels of IL-6 and TNF-alpha in bronchoalveolar lavage fluids.

Opaganib  was originally developed by U.S.-based Apogee Biotechnology Corp. and completed multiple successful preclinical studies in oncology, inflammation, GI, and radioprotection models, as well as a Phase 1 clinical study in cancer patients with advanced solid tumors and an additional Phase 1 study in multiple myeloma.

The development of opaganib  has been supported by grants and contracts from U.S. federal and state government agencies awarded to Apogee Biotechnology Corp., including from the NCI, BARDA, the U.S. Department of Defense and the FDA Office of Orphan Products Development.

The ongoing studies with opaganib  are registered on  www.ClinicalTrials.gov, a web-based service by the U.S. National Institute of Health, which provides public access to information on publicly and privately supported clinical studies.    

About RedHill Biopharma      

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik ® for opioid-induced constipation in adults[3], Talicia ® for the treatment of Helicobacter pylori (H. pylori) infection in adults[4], and Aemcolo ® for the treatment of travelers' diarrhea in adults[5]. RedHill's key clinical late-stage development programs include: (i) RHB-204,  with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) opaganib (Yeliva ®, ABC294640), a first-in-class SK2 selective inhibitor targeting multiple indications with positive Phase 2 COVID-19 data and an ongoing Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-107 (upamostat), a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn's disease; (v) RHB-102 (Bekinda ®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) RHB-106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com / https://twitter.com/RedHillBio.                

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words and includes statements regarding the timing of the reporting of a full analysis of the data from the U.S. Phase 2 trial evaluating opaganib, the timing of potential emergency use applications for opaganib and the timing of reporting of top-line data for the global Phase 2/3 study with opaganib. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the risk that the Company's COVID-19 Phase 2/3 study evaluating opaganib will not be successful; the risk of a delay in receiving top-line data from the Phase 2/3 study and in receiving data to support emergency use applications or in making such emergency use applications, if at all; the risk that data received from the Phase 2/3 study, even if successful, will not be sufficient to support filing or approval of emergency use applications or other marketing applications in certain or all geographical regions; the risk that the full analysis of data from the U.S. Phase 2 clinical study evaluating opaganib will be delayed or will differ from the preliminary data; the risk that the Company will not initiate the Phase 2/3 study for opaganib in certain geographies, will not expand this study to additional countries and that it will not be successful and that enrollment will be delayed; the risk that the Phase 2/3 study will not provide a clear picture of opaganib's potential in treating severe COVID-19; the risk that other COVID-19 patients treated with opaganib will not show any clinical improvement; the development risks of early-stage discovery efforts for a disease that is still little understood, including difficulty in assessing the efficacy of opaganib for the treatment of severe COVID-19, if at all; intense competition from other companies developing potential treatments and vaccines for COVID-19; the effect of a potential occurrence of patients suffering serious adverse events using opaganib, as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia ®; (v) the Company's ability to successfully commercialize and promote Movantik ®, Talicia ® and Aemcolo ®; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build and sustain its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and commercial products and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse events using investigative drugs under the Company's Expanded Access Program; and (xiv) competition from other companies and technologies within the Company's industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on March 4, 2020. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

References:

[1] Opaganib is an investigational new drug, not available for commercial distribution.

[2] Xia C. et al. Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice. Antiviral Res. 2018 Oct; 158:171-177. Ebenezer DL et al. Pseudomonas aeruginosa  stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury. Thorax. 2019 Jun;74(6):579-591.

[3] Full prescribing information for Movantik ® (naloxegol) is available at: www.Movantik.com.    

[4] Full prescribing information for Talicia ® (omeprazole magnesium, amoxicillin and rifabutin) is available at: www.Talicia.com.            

[5] Full prescribing information for Aemcolo ® (rifamycin) is available at: www.Aemcolo.com.

Logo: https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg    

 

Company contact:

Media contacts:

Adi Frish

U.S.: Bryan Gibbs, Finn Partners

Chief Corporate & Business Development Officer

+1 212 529 2236

RedHill Biopharma

bryan.gibbs@finnpartners.com

+972-54-6543-112

UK: Amber Fennell, Consilium

adi@redhillbio.com

+44 (0) 7739 658 783


fennell@consilium-comms.com

 

 

More News by PR Newswire India

Damm and Ball launch world's first Aluminium Stewardship Initiative certified beverage cans

LimaCorporate And HSS Partner To Open First Provider-based Design And 3D Printing Center For Complex Joint Reconstruction Surgery

WhiteHat Jr.'s search for Tech Leaders steered by Purple Quarter

Ampersand Group successfully concludes digital intervention, development across Nashik Anganwadis

Siply Launches Affordable Gold Savings Scheme with High Returns for the Masses

Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity

Aavishkaar Group dedicates its Group Impact Report 2020 to 55 Million women leaders in its ecosystem

Feedback plc: International expansion with appointment of two industry specialists in India

LexisNexis Risk Solutions Study Reveals Financial Crime Compliance Costs Across Asia-Pacific Region Increased 20.6% Year Over Year

Eight Manga Artists' Works Exhibited at Kansai Airport Starting March 20

Asia Pacific banks are ready to take advantage of truly digital cores - delivering competitive advantages beyond cost

Citizenship by Investment Funded Real Estate Developments Will Bolster Dominica's Tourism Offering

Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial

Cleaner, Clearer Pool and Spa Water

Gastops celebrates 3,500th engine sensor delivery for F-35 Lightning II

Amazfit T-Rex Pro: A Tough Military-grade Smartwatch with Endurance to Match Your Own and up to 18 Days' Battery Life[1]

Rugged Military-Grade Smartwatch is the Ultimate Partner for Challenging Military-Grade Obstacle Course, Amazfit Partners with Spartan

Meitra Hospital Redefines its Brand Identity

Second Star-studded Hank's Home Game Sees Jokes, Jibes and Showdowns in the Name of Charity at PokerStars.net

Goa Introduces Olectra Electric Buses in its fleet

Haier's Healthy Air Conditioners Rank Number One in Three Prestigious Euromonitor International Categories

AeC Lauded by Frost & Sullivan for Employing a Mix of Technology and Human Expertise to further strengthen its position in the Brazilian Customer Experience Outsourcing Market

Pharmactive Earns Acclaim from Frost & Sullivan for Helping People Improve their Cognitive Functions with its Saffron-based Ingredient, Affron®

HPE Lauded by Frost & Sullivan for Lowering the Risk of 5G Deployments

Uptake Recognized by Frost & Sullivan for Its Predictive Modeling Solutions for Medium-to-heavy-duty Vehicles

Brands are Redefining the Customer Experience by Adopting a Digital-first Approach

IIIT Hyderabad Announces M.Tech Program in Product Design and Management

U.S. Polo Assn. to Sponsor the Annual Lexus International Gay Polo Tournament Celebrating the Gay Polo League

Eagle Eye and Neptune Retail Solutions Enable a Better Digital Coupon Experience for Southeastern Grocers' Shoppers

Sinopec Signs Long-term Liquefied Natural Gas Deal of 2 Million Tons per Annum with Qatar Petroleum

Byogy Commissions Sustainable Low Carbon Jet Fuel Plant in Japan Advancing 'Alcohol to Jet' to Zero Carbon

Xinhua Silk Road: Changsha Economic and Technological Development Zone in C. China's Hunan unveils multiple measures to attract talents worldwide

AWE 2021: Haier Smart Home Brings Revolutionary Living Experience Empowered by its Smart Home Solution

New Research Reveals Top Investment Migration Program Options for HNWIs Seeking Health Security

V-Marc India Limited Initial Public Offering of Equity Shares opening on Thursday, March 25, 2021

Digital-First Tylko Raises €22 Million in Series C as Part of Its Commitment to Set New Standards in the Furniture Industry

Life Cycle Analysis of Corbion's AlgaPrime™ DHA Validates Lower Carbon Footprint Compared to Traditional Sources of Fish Oil

Logiq Partners with Comviva to Offer Digital Wallet and Payment Services to Millions of Mobile Users Across Indonesia

Diluent or Immuno-Reagent solutions for your diagnostic testing kits (Covid, Flu, etc.)

oneZero releases Algorithmic Pricing Module to give institutional clients even greater control

World Class Cocktail Festival: 2021 Homecoming

On World Water Day 2021, Sensus unveils exclusive whitepaper - 'Smart Cities need Smart Water'

Hexaware Technologies is Great Place to Work - certified

Ghodawat Consumer Earns a Prestigious Award; Bags 'India's Most Admirable Brand' Recognition

Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity

UST Provides Online Retail Platform Solution for UNIQLO India to Launch 'Shop From Home' Service

IAS Launches First Industry-Wide Digital Ad Verification Training Program

Bruce Lee's lost passion project 'The Silent Flute' to be produced by entrepreneur Jason Kothari

WZCC announces an exciting webinar with Mr. Piruz Khambatta, Chairman of Rasna, Hon. Consul General South Korea, Director GNFC, Chairman Rasna Foundation and Founder Trustee Areez Khambatta Benevolent Trust

HarperCollins is delighted to announce: Everything the Light Touches by Janice Pariat, publishing from Fourth Estate in October 2022

Crypto Liquidity Platform Black Ocean Opens Customer Whitelist

PathogenDx Applauded by Frost & Sullivan for Its Ultra-rapid COVID-19 Testing Platform, DetectX-Rv Test

Global Semiconductor Materials Market Sets New High of $55.3 Billion With 5% Expansion in 2020, SEMI Reports

Catalyst Welcomes Accenture CEO Julie Sweet As New Board Chair

Frost & Sullivan Opens Nominations for Itron Excellence in Resourcefulness Awards

Squirrels Boosts AirPlay, Miracast and Google Cast With All-New Reflector 4

Stockholm International Water Institute: Freshwater Thought Leader Sandra Postel awarded 2021 Stockholm Water Prize

Astral Foundation helps Hiwali get its first water pipeline after independence

Sirtex Medical announces new SIR-Spheres® DOORwaY-90 Study: The first prospective multicenter U.S.-based trial for registration as first-line treatment for hepatocellular carcinoma

Frost & Sullivan Experts Analyze Regional Tactics for Water and Sanitation for All by 2030

NEC Earns Acclaim from Frost & Sullivan for Adopting a Vector-based Approach to High-performance Computing with its SX-Aurora TSUBASA

Voyager Labs Partners with Microsoft to Provide AI SaaS Investigation Platforms to Empower Public Safety

Global Energy Prize 2021 - record number of participating countries

RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland

Summer Gold Coin Offer begins on KhelPlay Rummy

Planet Water Foundation Brings Life-Changing Access to Clean Drinking Water to Communities Across 5 Countries as Part of World Water Day Activation

RDIF and Virchow Biotech partner for production of Sputnik V vaccine in India

Sonata Software to tap the Customer Experience (CX) Market to fuel growth

Mana Projects Celebrating 21 Years of Real Estate Excellence

Avaya Acclaimed by Frost & Sullivan for Seizing Growth Opportunities with its Robust Portfolio of Intelligent Contact Center Solutions

Glenmark and Bausch Health join together to commercialize RYALTRIS ™ nasal spray in Canada

AVEVA and OSIsoft Combine to Unlock the Potential of Data to Drive Increased Performance for Industrial Organizations

Xinhua Silk Road: Nanjing Jiangbei New Area invites global partners to jointly promote dev. of life and health industry

Zalando Launches Spring Campaign to Laud Society's Champions & Celebrate Their Values

Hexaware Technologies Announces a Work Integrated Learning Program for Freshers

Empuls by Xoxoday integrates with Slack

India's Top Student Volunteers Felicitated At The 11th Annual Pramerica Spirit of Community Awards

Rajshri Entertainment to Make Its Wellness Content Available on Gaana as Podcasts

Plintron powers a unique educational initiative by SmartCentric

IBM Launches Fourth Annual Call for Code Global Challenge to Tackle Existential Threat of Climate Change

Product Analytics is the Number One Measurement of Digital Success, New Report By Harvard Business Review Analytic Services Sponsored by Amplitude Shows

SVKM's NMIMS Invites Applications for Post-Graduate Pharmacy Programs

PrettyLittleThing Turns Burj Khalifa Pink

Doctors Hospital Takes Action to Preserve Fair Competition After the Cayman Government Grants a Series of Financial Concessions

Maybelline New York Announces Storm Reid As Global Spokesmodel

The Craft Irish Whiskey Co. Sets the Record for the World's Most Expensive Whiskey Collection in Partnership With Fabergé

ZS PRIZE, a healthcare innovation programme, selects top 8 teams for jury evaluation and final winner announcement in April 2021

SUN Mobility and Zyngo partner to offer seamless last-mile delivery

India Nightlife Convention & Awards (INCA) concludes its 5th Edition in Goa

OKExChain welcomes Cosmostation validator node operator among six other partners to its rapidly expanding ecosystem

Voltas introduces the new 2021 range of Voltas Fresh Air Coolers; launches 'Ab Garmi Ke Mazey Lo, Bina Garmi Ke' campaign

Aster MIMS Calicut Offers Free Liver Transplant Surgeries to Children

'The Apprentice: ONE Championship Edition' to Premiere in India tomorrow, March 20th on Republic TV

APML issues pre-alert and guidelines to save innocent citizens from fake websites and fraudsters in packing and moving segment

GC to Increase Vinythai Shares through Delisting Tender Offer, Strengthening Downstream Chemicals Business, and Expanding Its Business in CLMV Market

Flexible workspaces to lease 3 million square feet of space in 2021: Colliers

RateGain Ranks in Deloitte Technology Fast50 For The Fifth Time

First Advantage launches Vendor Screening Solution

NMIMS Hyderabad Invites Applications for Common Entrance Tests - NMIMS- NPAT, NMIMS-CET and NMIMS-LAT - for Commerce, Pharmacy, & Law Programs

IAS Extends its Leadership in Brand Safety and Ad Fraud Protection with TAG Recertification

CITIC Networks Becomes Big Data Exchange (BDx) Connectivity Partner in Nanjing Data Center

ApiJect Systems, Corp., Announces Appointment of Global Branding Leader, Craig Cohon as Chief Strategy Officer

Encore® Launches Hybrid+, Setting A Global Standard For Hybrid Meeting & Event Experiences

New Report Discusses IT/OT Convergence for Telcos

SDI Adds Acteev Protect™ Masks to Portfolio of PPE As-a-Service(SM)

The 129th Canton Fair Prepares for a Virtual Return from April 15-24, 2021

Hitachi launches new range of Room Air Conditioners for the new-age consumers: 'One for everyone'

Five Business Strategies to Ensure Environment Safety and Leverage eWaste Management

Huawei Recognized as a 2021 Gartner Peer Insights Customers' Choice for WAN Edge Infrastructure

"Charm of Jiangsu" celebrated the 2021 Chinese New Year with overseas fans online

GameAnalytics Joins Huawei Ecosystem as the Latest Platform Partner

Frost & Sullivan's India Manufacturing Excellence Awards 2021 to Honor Future-Ready Factories

Adani Green Energy raises USD 1.35 billion in one of Asia's largest project financing deals

Reliance Securities named as India's 10 most promising share trading platforms of 2020

QuerySurge is Now Available in the Microsoft Azure Marketplace

XCMG Celebrates International Day of Happiness, Champions Employee Wellbeing with its Upgraded Total Health Program

ZestMoney Ranked Second Fastest Growing Technology Company in Deloitte Technology Fast 50 India 2020

Firescore Interactive to launch the hyper-casual gaming hub 'CrazyHubs India' in partnership with CrazyLabs

Technical clothing requirements for armed forces likely to be included in negative import list; keen to procure indigenised techno textiles: General Bipin Rawat

Frost & Sullivan Identifies the Top 5 Growth Opportunities in the Next-Generation Connected Car Industry

Trimble Announces Release of Tekla 2021 Structural BIM Software Solutions

Nespresso invests CHF 117 million in the expansion of its Avenches production center to meet growing consumer demand

FDI - Dental disaster: One year after first lockdowns dentists around the world confront the consequences of the COVID-19 pandemic on people's oral health: higher incidence of tooth decay and more advanced gum disease

Aeijaz Sodawala, CEO eZee Technosys gives an industry insider view-point on the Google Free Booking Link Program

Skootr Launches Skootr FinSave, A New Company To Meet Growing Demand For Financial Services In The Office Segment

LYRA last-mile connectivity solution for rural India

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Govt waives import duty on Remdesivir AP...
19 juveniles escape from isolation ward ...
Re-polling held in 4 polling stations in...
Karnataka should not shy away from lockd...
SC to take up only urgent matters from A...
'Overwhelming pendency': SC paves way fo...
More...    
 
 Top Stories
'People are crying for medicines, o... 
Maharashtra may announce complete l... 
Stock markets shut on account of Ra... 
India reports nearly 3-lakh fresh C... 
UNGA president reaffirms support fo... 
Madhuri Dixit performs to viral 'Ba... 
Argentina reports over 29,000 new C... 
DRDO to set up two 500-bed COVID ho...